http://publicationslist.org/data/helen.gogas/atom.xml Helen Gogashttp://publicationslist.org/helen.gogas$basepathfavicon.icoRecent additions to Helen Gogas's PublicationsList.org pagehttp://publicationslist.org/publications.png2010-10-27T09:11:36Z http://publicationslist.org/helen.gogas/refid4 2010-10-27T09:02:20Z

Hyperthermic isolated limb perfusion with TNF-alpha and melphalan (TM-HILP) is a complicated surgical procedure. Herein, we present the experience of the Hellenic collaborating centers with TM-HILP for inoperable in-transit melanoma and soft tissue sarcoma (STS) of the extremities to examine safety and feasibility of collaborating as a multi-institutional group for future research studies. From 20...<br/><br/>Konstantinos Lasithiotakis, George Economou, Helen Gogas, Christos Ioannou, Konstantinos Perisynakis, Dimitrios Filis, Ourania Kastana, Dimitrios Bafaloukos, Marios Decatris, Nikolaos Catodritis, Konstantina Frangia, George Papadakis, Michael Magarakis, Dimosthenis Tsoutsos, Emmanuel Chrysos, George Chalkiadakis, Odysseas Zoras (2010) <i>Oncol Rep</i> <i></i> <i></i> 23: 4 1077-1083<br/>

http://publicationslist.org/helen.gogas/refid2 2010-10-27T09:02:20Z

PURPOSE: This phase II study sought to evaluate the efficacy of the paclitaxel-carboplatin combination as neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). PATIENTS AND METHODS: A total of 46 patients with LABC and inflammatory breast cancer (IBC) received 6 cycles of paclitaxel 175 mg/m2, followed by carboplatin, at an area under the curve of 6, before mastectomy. T...<br/><br/>Helen Gogas, Dimitrios Pectasides, Ioannis Kostopoulos, Evangelos Lianos, Dimosthenis Skarlos, George Papaxoinis, Mattheos Bobos, Haralabos P Kalofonos, Kalliopi Petraki, Kitty Pavlakis, Dimitrios Bafaloukos, George Fountzilas (2010) <i>Clin Breast Cancer</i> <i></i> <i></i> 10: 3 230-237<br/>

http://publicationslist.org/helen.gogas/refid3 2010-10-27T09:02:20Z

INTRODUCTION: The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). METHODS: Pre-treatment BMD of 213 patients with hormone receptor-positive BC was evaluated at lumbar spine (LS) and hip (HP). Patients wer...<br/><br/>Christos Markopoulos, Evagelos Tzoracoleftherakis, Athanassios Polychronis, Basileios Venizelos, Urania Dafni, Grigorios Xepapadakis, John Papadiamantis, Vasilios Zobolas, John Misitzis, Kyriakos Kalogerakos, Angeliki Sarantopoulou, Nikolaos Siasos, Dimitrios Koukouras, Zoh Antonopoulou, Spyros Lazarou, Helen Gogas (2010) <i>Breast Cancer Res</i> <i></i> <i></i> 12: 2 <br/>

http://publicationslist.org/helen.gogas/refid1 2010-10-27T09:02:20Z

BACKGROUND: Interferon is approved for adjuvant treatment of patients with stage IIB/III melanoma. The identification of predictive markers that would permit selection of patients would be beneficial. Specific human leukocyte antigen (HLA) class I and II antigens have previously shown an association with response to therapy or overall survival of patients with metastatic melanoma. METHODS: A total...<br/><br/>Helen Gogas, John M Kirkwood, Christine S Falk, Urania Dafni, Vernon K Sondak, Dimosthenis Tsoutsos, Alexandros Stratigos, Christos Markopoulos, Dimitrios Pectasides, Maria Spyropoulou-Vlachou (2010) <i>Cancer</i> <i></i> <i></i> 116: 18 4326-4333<br/>

http://publicationslist.org/helen.gogas/refid14 2010-10-27T09:02:20Z

Herein, we expound the theory of circulating melanoma cells (CMCs) and their detection with reverse transcription polymerase chain reaction as a molecular staging approach. We discuss the molecular markers that have been used for CMC detection focusing on the use of these markers for multiplex detection analysis. Finally, we comment on the contradictory data of CMC detection studies in the literat...<br/><br/>Adrianos Nezos, Peter Lembessis, Antigone Sourla, Nikolaos Pissimissis, Helen Gogas, Michael Koutsilieris (2009) <i>Clin Chem Lab Med</i> <i></i> <i></i> 47: 1 1-11<br/>

http://publicationslist.org/helen.gogas/refid13 2010-10-27T09:02:20Z

PURPOSE: A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique for the incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) therapy for the initial 4 weeks. This is the only trial that has shown prolongation of overall survival and relapse-free survival (RFS) in comparison with observation. Analysis of the hazard curves for RFS and overal...<br/><br/>Dimitrios Pectasides, Urania Dafni, Dimitrios Bafaloukos, Dimosthenis Skarlos, Aristidis Polyzos, Dimosthenis Tsoutsos, Haralambos Kalofonos, George Fountzilas, Petros Panagiotou, George Kokkalis, Othon Papadopoulos, Ourania Castana, Stefanos Papadopoulos, Elias Stavrinidis, Georgia Vourli, John Ioannovich, Helen Gogas (2009) <i>J Clin Oncol</i> <i></i> <i></i> 27: 6 939-944<br/>

http://publicationslist.org/helen.gogas/refid18 2010-10-27T09:02:20Z

BACKGROUND: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting. PATIENTS AND METHODS: Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n=77) or ta...<br/><br/>C Markopoulos, A Polychronis, U Dafni, D Koukouras, V Zobolas, E Tzorakoleftherakis, G Xepapadakis, H Gogas (2009) <i>Ann Oncol</i> <i></i> <i></i> 20: 1 49-55<br/>

http://publicationslist.org/helen.gogas/refid22 2010-10-27T09:02:20Z

BACKGROUND: Effective anthracycline-free combinations need to be evaluated in metastatic breast cancer (MBC), due to the increased number of patients treated with anthracycline-based adjuvant chemotherapy. PATIENTS AND METHODS: Patients with MBC were randomized to paclitaxel and carboplatin (PCb) every 3 weeks or docetaxel and gemcitabine (GDoc) every 3 weeks or weekly paclitaxel (Pw). Trastuzumab...<br/><br/>G Fountzilas, U Dafni, M A Dimopoulos, A Koutras, D Skarlos, P Papakostas, H Gogas, D Bafaloukos, A Kalogera-Fountzila, E Samantas, E Briasoulis, D Pectasides, N Maniadakis, F Matsiakou, G Aravantinos, C Papadimitriou, M Karina, C Christodoulou, P Kosmidis, H P Kalofonos (2009) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 115: 1 87-99<br/>

http://publicationslist.org/helen.gogas/refid12 2010-10-27T09:02:20Z

OBJECTIVE: Combination of trastuzumab and anthracyclines in metastatic breast cancer (MBC) is precluded due to cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is the least cardiotoxic among the anthracyclines. We performed a phase II study of trastuzumab and PLD with biomarker evaluation. METHODS: Patients with MBC and HER2 overexpression, assessed as 3+ at local laboratories, received trast...<br/><br/>Christos Christodoulou, Ioannis Kostopoulos, Haralabos P Kalofonos, Evangelos Lianos, Mattheos Bobos, Evangelos Briasoulis, Helen Gogas, Evangelia Razis, Dimosthenis V Skarlos, George Fountzilas (2009) <i>Oncology</i> <i></i> <i></i> 76: 4 275-285<br/>

http://publicationslist.org/helen.gogas/refid20 2010-10-27T09:02:20Z

The SLC24A5 gene, the human orthologue of the zebrafish golden gene, has been shown to play a key role in human pigmentation. In this study, we investigate the prevalence of the variant allele rs1426654 in a selected sample of Greek subjects. Allele-specific polymerase chain reaction was performed in peripheral blood samples from 158 attendants of a dermatology outpatient service. The results were...<br/><br/>Gerasimos Dimisianos, Irene Stefanaki, Vicky Nicolaou, Vana Sypsa, Christina Antoniou, Myrto Poulou, Othon Papadopoulos, Helen Gogas, Emmanouel Kanavakis, Electra Nicolaidou, Andreas D Katsambas, Alexander J Stratigos (2009) <i>Exp Dermatol</i> <i></i> <i></i> 18: 2 175-177<br/>

http://publicationslist.org/helen.gogas/refid19 2010-10-27T09:02:20Z

BACKGROUND: Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. We sought to study the predictive significance and correlations of transcriptional profiling of the ER, PgR and microtubule-associated protein Tau (MAP-Tau) genes in early breast ...<br/><br/>George Pentheroudakis, Konstantine T Kalogeras, Ralph M Wirtz, Irene Grimani, George Zografos, Helen Gogas, Udo Stropp, Dimitrios Pectasides, Dimosthenis Skarlos, Guido Hennig, Epaminondas Samantas, Dimitrios Bafaloukos, Pavlos Papakostas, Haralabos P Kalofonos, Nicholas Pavlidis, George Fountzilas (2009) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 116: 1 131-143<br/>

http://publicationslist.org/helen.gogas/refid15 2010-10-27T09:02:20Z

BACKGROUND: Oxaliplatin has become one of the major cytotoxic agents for the treatment of gastrointestinal tumors. As a result, several cases of the so-called oxaliplatin-associated hypersensitivity reaction have been documented. PATIENTS AND METHODS: We have retrospectively evaluated and characterized these reactions in our patient group by reviewing the files of 1,224 patients exposed to an oxal...<br/><br/>Aristides Polyzos, Nikolas Tsavaris, Hellen Gogas, John Souglakos, Lambros Vambakas, Nikolaos Vardakas, Kostas Polyzos, Christos Tsigris, Demetrios Mantas, Antonios Papachristodoulou, Nikolas Nikiteas, John G Karavokyros, Evangelos Felekouras, John Griniatsos, Athanasios Giannopoulos, Gregory Kouraklis (2009) <i>Oncology</i> <i></i> <i></i> 76: 1 36-41<br/>

http://publicationslist.org/helen.gogas/refid11 2010-10-27T09:02:20Z

BACKGROUND: In most Western populations, 5-10% of all breast cancer cases can be attributed to major genetic factors such as predisposing mutations in BRCA1 and BRCA2, with early-onset cases generally considered as an indicator of genetic susceptibility. Specific BRCA1 and BRCA2 mutations or different mutation frequencies have been identified in specific populations and ethnic groups. Previous stu...<br/><br/>S Armaou, M Pertesi, F Fostira, G Thodi, P S Athanasopoulos, S Kamakari, A Athanasiou, H Gogas, D Yannoukakos, G Fountzilas, I Konstantopoulou (2009) <i>Br J Cancer</i> <i></i> <i></i> 101: 1 32-37<br/>

http://publicationslist.org/helen.gogas/refid8 2010-10-27T09:02:20Z

BACKGROUND: The role of combination chemotherapy regimens in the management of ovarian cancer patients with tumors previously exposed to platinum compounds and paclitaxel has not yet been defined. The present phase II study evaluated the activity and toxicity of a gemcitabine-ifosfamide-cisplatin combination in the aforementioned group of patients. Given the in vitro and in vivo synergism between ...<br/><br/>Aristides Polyzos, Nikolas Tsavaris, Helen Gogas, Antonios Lagadas, Kostas Polyzos, Kostas Giannakopoulos, Evangelos Felekouras, Christos Tsigris, Theodoros Karatzas, Othon Papadopoulos, Athanasios Giannopoulos (2009) <i>Anticancer Res</i> <i></i> <i></i> 29: 7 2681-2686<br/>

http://publicationslist.org/helen.gogas/refid5 2010-10-27T09:02:20Z

Biomarkers are tumour- or host-related factors that correlate with tumour biological behaviour and patient prognosis. High-throughput analytical techniques--DNA and RNA microarrays--have identified numerous possible biomarkers, but their relevance to melanoma progression, clinical outcome and the selection of optimal treatment strategies still needs to be established. The review discusses a possib...<br/><br/>H Gogas, A M M Eggermont, A Hauschild, P Hersey, P Mohr, D Schadendorf, A Spatz, R Dummer (2009) <i>Ann Oncol</i> <i></i> <i></i> 20 Suppl 6: vi8-v13<br/>

http://publicationslist.org/helen.gogas/refid6 2010-10-27T09:02:20Z

The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon (IFN) has shown an effect on relapse-free survival (RFS) in several clinical trials; however, without a clinically significant effect on overall survival (OS). A recently c...<br/><br/>A M M Eggermont, A Testori, J Marsden, P Hersey, I Quirt, T Petrella, H Gogas, R M MacKie, A Hauschild (2009) <i>Ann Oncol</i> <i></i> <i></i> 20 Suppl 6: vi30-vi34<br/>

http://publicationslist.org/helen.gogas/refid10 2010-10-27T09:02:20Z

INTRODUCTION: Extended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially alter the lipid profile of postmenopausal patients and thus increase the risk of developing cardiovascular disease. In this study, a subprotocol of the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial, we compared the effect of the steroidal aromatase inactivator exe...<br/><br/>Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou, Helen Gogas (2009) <i>Breast Cancer Res</i> <i></i> <i></i> 11: 3 <br/>

http://publicationslist.org/helen.gogas/refid9 2010-10-27T09:02:20Z

PURPOSE OF REVIEW: There is a critical need for greater understanding of the immunological and disease-related variables that predict clinical benefit from interferon alfa-2b. The identification of predictive markers that permit selection of patients who are most likely to benefit from interferon alfa would allow us to avoid exposing nonresponsive patients to the toxicity of treatment unassociated...<br/><br/>Helen Gogas, John M Kirkwood (2009) <i>Curr Opin Oncol</i> <i></i> <i></i> 21: 2 138-143<br/>

http://publicationslist.org/helen.gogas/refid7 2010-10-27T09:02:20Z

There is no standard treatment for breast cancer patients whose tumors have been exposed both to anthracyclines and taxanes. Oxaliplatin shows synergism with 5-fluorouracil (5-FU) and capecitabine is an oral prodrug of 5-FU with known efficacy in pretreated patients. This phase II trial studied the efficacy and toxicity of the oxaliplatin-capecitabine combination as salvage treatment in breast can...<br/><br/>Aristides Polyzos, Helen Gogas, Christos Markopoulos, Nikolas Tsavaris, Othon Papadopoulos, Kostas Polyzos, Athanasios Giannopoulos (2009) <i>Anticancer Res</i> <i></i> <i></i> 29: 7 2851-2856<br/>

http://publicationslist.org/helen.gogas/refid25 2010-10-27T09:02:20Z

Interferon-alpha-2b (IFNalpha2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the mana...<br/><br/>Axel Hauschild, Helen Gogas, Ahmad Tarhini, Mark R Middleton, Alessandro Testori, Brigitte Dréno, John M Kirkwood (2008) <i>Cancer</i> <i></i> <i></i> 112: 5 982-994<br/>

http://publicationslist.org/helen.gogas/refid37 2010-10-27T09:02:20Z

127 Greek breast/ovarian cancer families were screened for germline BRCA1/2 mutations by dHPLC followed by direct sequencing. Our results indicated 16 and 5 breast/ovarian cancer families bearing deleterious mutations in the BRCA1 and BRCA2 genes, respectively. Two novel BRCA2 germline mutations (G4X and 3783del10) are reported here for the first time. Subsequent compilation of our present finding...<br/><br/>Irene Konstantopoulou, Theodore Rampias, Angela Ladopoulou, George Koutsodontis, Sophia Armaou, Theodore Anagnostopoulos, George Nikolopoulos, Smaragda Kamakari, George Nounesis, Antonis Stylianakis, Charisios Karanikiotis, Evangelia Razis, Helen Gogas, Antonios Keramopoulos, Vassiliki Gaki, Christos Markopoulos, Dimosthenis Skarlos, Nikos Pandis, Thalia Bei, Iordanis Arzimanoglou, George Fountzilas, Drakoulis Yannoukakos (2008) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 107: 3 431-441<br/>

http://publicationslist.org/helen.gogas/refid31 2010-10-27T09:02:20Z

BACKGROUND: Solar radiation has been identified as a principal factor for the causation of melanoma, whereas changing lifestyle patterns associated with obesity and diabetes might also contribute to the increasing incidence of the malignancy. No study has investigated the role of leptin, a hormone whose levels increase in obesity and which has also been related to cancer. PATIENTS AND METHODS: Fif...<br/><br/>H Gogas, M Trakatelli, N Dessypris, A Terzidis, A Katsambas, G P Chrousos, E T Petridou (2008) <i>Ann Oncol</i> <i></i> <i></i> 19: 2 384-389<br/>

http://publicationslist.org/helen.gogas/refid29 2010-10-27T09:02:20Z

BACKGROUND: A randomized phase III trial in high-risk breast cancer patients was conducted, to further explore the impact of dose-density in the adjuvant treatment for breast cancer. The safety analysis is presented. PATIENTS AND METHODS: From October 2000 until June 2005, 1121 node-positive patients were randomized to sequential dose-dense epirubicin 110 mg/m(2) and paclitaxel (Taxol, Bristol Mye...<br/><br/>G Fountzilas, U Dafni, H Gogas, H Linardou, H P Kalofonos, E Briasoulis, D Pectasides, E Samantas, D Bafaloukos, G P Stathopoulos, M Karina, C Papadimitriou, D Skarlos, N Pisanidis, P Papakostas, C Markopoulos, E Tzorakoeleftherakis, K Dimitrakakis, P Makrantonakis, N Xiros, A Polichronis, I Varthalitis, C Karanikiotis, A M Dimopoulos (2008) <i>Ann Oncol</i> <i></i> <i></i> 19: 5 853-860<br/>

http://publicationslist.org/helen.gogas/refid24 2010-10-27T09:02:20Z

OBJECTIVES: Limited data exist about the risk factors of melanoma in the Greek population. We investigated the association of melanoma with phenotypic and solar indices in this darker skin population residing in an environment of high ambient ultraviolet radiation. METHODS: Our study included 200 sporadic melanoma cases and 200 age-, sex-matched control subjects. Information on history of sun expo...<br/><br/>Vasiliki A Nikolaou, Vana Sypsa, Irene Stefanaki, Helen Gogas, Othon Papadopoulos, Dorothea Polydorou, Michaela Plaka, Dimosthenis Tsoutsos, Anastasia Dimou, Eleni Mourtzoukou, Valantis Korfitis, Eftihia Hatziolou, Christina Antoniou, Angelos Hatzakis, Andreas Katsambas, Alexander J Stratigos (2008) <i>Cancer Causes Control</i> <i></i> <i></i> 19: 7 671-679<br/>

http://publicationslist.org/helen.gogas/refid21 2010-10-27T09:02:20Z

PURPOSE: Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States. DESIGN: Tumor evasion of host immune responses, and strategies for overcoming tumor-induced immunosuppression are reviewed. Several novel immunotherapies currently in wor...<br/><br/>John M Kirkwood, Ahmad A Tarhini, Monica C Panelli, Stergios J Moschos, Hassane M Zarour, Lisa H Butterfield, Helen J Gogas (2008) <i>J Clin Oncol</i> <i></i> <i></i> 26: 20 3445-3455<br/>

http://publicationslist.org/helen.gogas/refid16 2010-10-27T09:02:20Z

BACKGROUND: A number of studies have shown that absence of myelotoxicity during chemotherapy is associated with worse outcome for various types of cancer, including carcinoma of the breast. The aim of this study was to determine whether myelosuppression in patients being treated with chemotherapy for advanced breast cancer has an impact on their prognosis. PATIENTS AND METHODS: A retrospective rev...<br/><br/>Angelos K Koutras, George Fountzilas, Urania Dafni, Meletios A Dimopoulos, Dimitrios Pectasides, George Klouvas, Pavlos Papakostas, Paris Kosmidis, Epaminondas Samantas, Helen Gogas, Evangelos Briasoulis, Georgia Vourli, Theodoros Petsas, Nikolaos Xiros, Haralabos P Kalofonos (2008) <i>Anticancer Res</i> <i></i> <i></i> 28: 5B 2913-2920<br/>

http://publicationslist.org/helen.gogas/refid23 2010-10-27T09:02:20Z

BACKGROUND: Glycogen-rich carcinoma of the breast is a rare histological subtype of breast cancer, usually reported to have poor prognosis. CASE PRESENTATION: We present the case of a 59-year-old woman who underwent a mastectomy for a 3.5 cm clinically palpable left breast carcinoma, originally diagnosed as fibroadenoma on a screening mammogram four years before presentation. Diagnosis of clear ce...<br/><br/>Christos Markopoulos, Dimitris Mantas, T Philipidis, Efstatios Kouskos, Zoi Antonopoulou, Ml Hatzinikolaou, Helen Gogas (2008) <i>World J Surg Oncol</i> <i></i> <i></i> 6: <br/>

http://publicationslist.org/helen.gogas/refid17 2010-10-27T09:02:20Z

The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RNA was extracted from 268 formalin-fixed paraffin-embedded (FFPE) tumour tissue samples of high-risk breast cancer patients enrolled in the randomi...<br/><br/>A K Koutras, K T Kalogeras, M-A Dimopoulos, R M Wirtz, U Dafni, E Briasoulis, D Pectasides, H Gogas, C Christodoulou, G Aravantinos, G Zografos, E Timotheadou, P Papakostas, H Linardou, E Razis, T Economopoulos, H P Kalofonos, G Fountzilas (2008) <i>Br J Cancer</i> <i></i> <i></i> 99: 11 1775-1785<br/>

http://publicationslist.org/helen.gogas/refid36 2010-10-27T09:02:20Z

AIM: Melanoma, a malignancy with steadily increasing prevalence, has been associated not only with sun exposure but also with phenotypic characteristics including obesity. Adiponectin, an adipocyte secreted endogenous insulin sensitizer, has been found to play a protective role in several obesity related cancers but has not yet been studied in relation to melanoma. We investigated the association ...<br/><br/>C S Mantzoros, M Trakatelli, H Gogas, N Dessypris, A Stratigos, G P Chrousos, E Th Petridou (2007) <i>Eur J Cancer</i> <i></i> <i></i> 43: 9 1430-1436<br/>

http://publicationslist.org/helen.gogas/refid34 2010-10-27T09:02:20Z

BACKGROUND: The role of combination chemotherapy regimens in the management of ovarian cancer patients with tumors previously exposed to platinum compounds and paclitaxel has not yet been defined. The present phase II study evaluated the activity and toxicity of a paclitaxel-ifosfamide-cisplatin combination in the aforementioned group of patients. Given the in vitro and in vivo synergism between t...<br/><br/>Aristides Polyzos, Christos Kosmas, Nikolas Tsavaris, Helen Toufexi, Antonios Lagadas, Helen Gogas, Kostas Giannakopoulos, Gregory Kouraklis, John Griniatsos, Evagelos Felekouras, Christos Tsigris, Nikolas Nikiteas, Othon Papadopoulos, Athanasios Giannopoulos (2007) <i>Anticancer Res</i> <i></i> <i></i> 27: 3B 1645-1651<br/>

http://publicationslist.org/helen.gogas/refid40 2010-10-27T09:02:20Z

Melanoma is a neoplasm with a rising incidence. Early-stage melanoma is curable, but advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced disease have a short median survival. Systemic therapy remains unsatisfactory, inducing complete durable responses in a small minority of patients. For the current review, the authors focused on the current role of cytotoxic c...<br/><br/>Helen J Gogas, John M Kirkwood, Vernon K Sondak (2007) <i>Cancer</i> <i></i> <i></i> 109: 3 455-464<br/>

http://publicationslist.org/helen.gogas/refid39 2010-10-27T09:02:20Z

BACKGROUND: p53 has a common polymorphism at amino acid 72, encoding either arginine or proline. p53Arg and p53Pro exhibit differences in various biological activities, such as cell-cycle arrest and induction of apoptosis. Numerous epidemiological studies have examined the role of this polymorphism in several human malignancies, including cutaneous cancers, with contradictory results. OBJECTIVES: ...<br/><br/>I Stefanaki, A J Stratigos, G Dimisianos, V Nikolaou, O Papadopoulos, D Polydorou, H Gogas, D Tsoutsos, P Panagiotou, E Kanavakis, C Antoniou, A D Katsambas (2007) <i>Br J Dermatol</i> <i></i> <i></i> 156: 2 357-362<br/>

http://publicationslist.org/helen.gogas/refid26 2010-10-27T09:02:20Z

Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable nonsmall cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy following induction with non-platinum chemotherapy in patients with inoperable locally advanced NSCLC. PATIENTS AND METHODS: All patients with locally advance...<br/><br/>P Kosmidis, G Fountzilas, S Baka, E Samantas, A M Dimopoulos, H Gogas, D Skarlos, P Papacostas, J Boukovinas, Ch Bakogiannis, P Pantelakos, H Athanasiou, D Misailidou, P Tsekeris, N Pavlidis (2007) <i>Anticancer Res</i> <i></i> <i></i> 27: 6C 4391-4395<br/>

http://publicationslist.org/helen.gogas/refid27 2010-10-27T09:02:20Z

BACKGROUND: To assess the prognostic and predictive significance of HER-1/EGFR protein levels in high-risk patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy. METHODS: 595 high-risk breast cancer patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF). Disease-free survival (DFS) was the primary end point. HER...<br/><br/>Olympia Tzaida, Helen Gogas, Urania Dafni, Aspasia Kyroudi, Irene Papaspyrou, Vasiliki Kyriakou, Vasiliki Malamou-Mitsi, Maria Alamani, Chrisoula Skopa, Ioannis Kostopoulos, Efstathios Kastritis, Dimitrios Pectasides, Evangelos Briasoulis, Haralabos P Kalofonos, Gerasimos Aravantinos, George Fountzilas, Petroula Arapantoni-Dadioti (2007) <i>Oncology</i> <i></i> <i></i> 72: 5-6 388-396<br/>

http://publicationslist.org/helen.gogas/refid33 2010-10-27T09:02:20Z

Chemotherapy is an established modality in the management of patients with advanced gastric cancer but the optimal regimen has not been defined yet. Platinum and the anthracyclines and more recently docetaxel have shown activity in this tumor. The primary objective of this phase II study was to assess the efficacy and safety of an intensified regimen of weekly docetaxel/epirubicin/carboplatin (DEC...<br/><br/>Thomas Makatsoris, Pavlos Papakostas, Haralabos P Kalofonos, Ioannis Xanthakis, Dimitrios Tsavdaridis, Gerasimos Aravantinos, Helen Gogas, George Klouvas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas (2007) <i>Med Oncol</i> <i></i> <i></i> 24: 3 301-307<br/>

http://publicationslist.org/helen.gogas/refid28 2010-10-27T09:02:20Z

Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer. The aim of this study was to evaluate the efficacy and safety of the combination as second or third line treatment in patients with metastatic breast cancer (MBC). Fifty-one previously treated patients with MBC were enrolled from October 2001 to May 2004 and 48 were eligi...<br/><br/>A Onyenadum, H Gogas, C Markopoulos, D Bafaloukos, G Aravantinos, M Mantzourani, A Koutras, E Tzorakoelefterakis, N Xiros, T Makatsoris, G Fountzilas, H P Kalofonos (2007) <i>J Chemother</i> <i></i> <i></i> 19: 5 582-589<br/>

http://publicationslist.org/helen.gogas/refid32 2010-10-27T09:02:20Z

Skin tumors comprise the largest group of malignancies of the head. Despite the accessibility of such lesions, the treatment of neglected, far advanced cancers, many of which have extended deeply into the facial bones and skull, is often required. The key to the cure of malignant tumors of the head is an accurate diagnosis and evaluation of the margins of an excised tumor. Reconstructive surgery o...<br/><br/>Othon Papadopoulos, Petros Konofaos, Chrisostomos Chrisostomidis, Grigorios Champsas, Marios Frangoulis, Petros Karakitsos, Alexandros Stratigos, Helen Gogas, Andreas Katsambas, Alkiviadis Kostakis (2007) <i>J Craniofac Surg</i> <i></i> <i></i> 18: 5 1021-1033<br/>

http://publicationslist.org/helen.gogas/refid49 2010-10-27T09:02:20Z

The expressions ofp27Kip1 (p27) and p21waf1 (p21) cyclin-dependent kinase inhibitors and p53 were examined in a series of 170 node-negative breast carcinomas (NNBCs) to evaluate their prognostic significance. Low nuclear (p27TN) and cytoplasmic (p27TC) p27 expressions were noted in 66% and 81% of NNBCs, respectively. p21 and p53 overexpressions were detected in 56% and 26%, respectively. Low p27TN...<br/><br/>Helen P Kourea, Angelos K Koutras, Vassiliki Zolota, Irene Grimani, Evangelos Tzoracoeleftherakis, Dimitrios Koukouras, George Fountzilas, Helen Gogas, Kyriakos Kyriakou, Adamos Adamou, Haralambos P Kalofonos (2006) <i>Anticancer Res</i> <i></i> <i></i> 26: 2B 1657-1668<br/>

http://publicationslist.org/helen.gogas/refid48 2010-10-27T09:02:20Z

P Sideris, S Tassiopoulos, N Sakellaropoulos, A Androulaki, E Variami, H Gogas, M Kanakis, G Vaiopoulos (2006) <i>Ann Hematol</i> <i></i> <i></i> 85: 8 555-556<br/>

http://publicationslist.org/helen.gogas/refid50 2010-10-27T09:02:20Z

Individuals with melanocortin 1 receptor (MC1R) gene variants have been shown to carry an increased risk for the development of melanoma. In this study, we investigated the relationship of MC1R gene variants and the risk of melanoma in 123 melanoma patients and 155 control subjects from Greece. The entire MC1R gene was sequenced for polymorphisms and the results were correlated with host factors a...<br/><br/>Alexander J Stratigos, Gerasimos Dimisianos, Vasiliki Nikolaou, Mirto Poulou, Vana Sypsa, Irene Stefanaki, Othon Papadopoulos, Dorothea Polydorou, Michaela Plaka, Eleftheria Christofidou, Helen Gogas, Dimosthenis Tsoutsos, Ourania Kastana, Christina Antoniou, Angelos Hatzakis, Emmanouil Kanavakis, Andreas D Katsambas (2006) <i>J Invest Dermatol</i> <i></i> <i></i> 126: 8 1842-1849<br/>

http://publicationslist.org/helen.gogas/refid52 2010-10-27T09:02:20Z

BACKGROUND: Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity. We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b. METHODS: We enrolled 200 patients in a substudy of a larger, ongoing randomized trial. Blood was obtained before the initia...<br/><br/>Helen Gogas, John Ioannovich, Urania Dafni, Catherine Stavropoulou-Giokas, Konstantina Frangia, Dimosthenis Tsoutsos, Petros Panagiotou, Aristidis Polyzos, Othonas Papadopoulos, Alexandros Stratigos, Christos Markopoulos, Dimitrios Bafaloukos, Dimitrios Pectasides, George Fountzilas, John M Kirkwood (2006) <i>N Engl J Med</i> <i></i> <i></i> 354: 7 709-718<br/>

http://publicationslist.org/helen.gogas/refid53 2010-10-27T09:02:20Z

INTRODUCTION: Breast cancer patients developing liver metastases have traditionally been considered to make up a poor prognosis group with median survival rates of less than 6 months. We retrospectively analysed clinicopathologic characteristics of 500 women with metastatic breast cancer and liver deposits upon administration of first-line chemotherapy in the 90s. We sought to examine the epidemio...<br/><br/>George Pentheroudakis, George Fountzilas, Dimitrios Bafaloukos, Vasiliki Koutsoukou, Dimitrios Pectasides, Dimosthenis Skarlos, Epaminondas Samantas, Haralabos P Kalofonos, Helen Gogas, Nicholas Pavlidis (2006) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 97: 3 237-244<br/>

http://publicationslist.org/helen.gogas/refid47 2010-10-27T09:02:20Z

Gemcitabine and mitoxantrone have both shown significant antitumor activity in patients with breast cancer. The aim of this study was to evaluate the efficacy and safety of this combination as second or third-line treatment in patients with metastatic breast cancer (MBC). Forty-six previously treated patients with MBC were enrolled from June 2000 to November 2002. Mean age was 56 years and ECOG pe...<br/><br/>A Onyenadum, H Gogas, P Kosmidis, G Aravantinos, D Bafaloukos, H Bacoyiannis, C Markopoulos, A Koutras, E Tzorakoelefterakis, T Makatsoris, G Fountzilas, H P Kalofonos (2006) <i>J Chemother</i> <i></i> <i></i> 18: 2 192-198<br/>

http://publicationslist.org/helen.gogas/refid51 2010-10-27T09:02:20Z

PURPOSE: To assess the prognostic and predictive significance of HER-2 overexpression and high expression of VEGF in high-risk patients with breast cancer treated with dose-dense sequential chemotherapy. PATIENTS AND METHODS: From June 1997 until November 2000, 595 patients were randomized to three cycles of epirubicin (E) 110 mg/m2 followed by three cycles of paclitaxel (T) 250 mg/m2 followed by ...<br/><br/>Ioannis Kostopoulos, Petroula Arapantoni-Dadioti, Helen Gogas, Savvas Papadopoulos, Vasiliki Malamou-Mitsi, Chrisoula D Scopa, Sofia Markaki, Evangelia Karagianni, Vasiliki Kyriakou, Anastasia Margariti, Elisavet Kyrkou, Kitty Pavlakis, Thomas Zaramboukas, Anna Skordalaki, Antonia Bourli, Christos Markopoulos, Dimitrios Pectasides, Meletios A Dimopoulos, Dimosthenis Skarlos, George Fountzilas (2006) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 96: 3 251-261<br/>

http://publicationslist.org/helen.gogas/refid44 2010-10-27T09:02:20Z

PURPOSE: To assess the prognostic and predictive significance of p53 and Bcl-2 protein expression in high risk patients with breast cancer treated with dose-dense sequential chemotherapy. PATIENTS AND METHODS: From June 1997 until November 2000, 595 patients were randomized to three cycles of epirubicin (E) 110 mg/m2 followed by three cycles of paclitaxel (P) 250 mg/m2 followed by three cycles of ...<br/><br/>V Malamou-Mitsi, H Gogas, U Dafni, A Bourli, T Fillipidis, M Sotiropoulou, D Vlachodimitropoulos, S Papadopoulos, O Tzaida, G Kafiri, V Kyriakou, S Markaki, I Papaspyrou, E Karagianni, K Pavlakis, T Toliou, Cd Scopa, P Papakostas, D Bafaloukos, C Christodoulou, G Fountzilas (2006) <i>Ann Oncol</i> <i></i> <i></i> 17: 10 1504-1511<br/>

http://publicationslist.org/helen.gogas/refid41 2010-10-27T09:02:20Z

The role of docetaxel in combination with cisplatin in the management of gastric cancer resistant to first-line chemotherapy has not yet been defined. This multicenter prospective phase II study evaluated the activity and toxicity of the docetaxel-cisplatin combination in gastric cancer patients, whose tumors were primarily resistant to first-line chemotherapy or had tumor recurrence after chemoth...<br/><br/>Aristides Polyzos, Nikolas Tsavaris, Christos Kosmas, Kostas Polyzos, Athanasios Giannopoulos, Evangelos Felekouras, Nikolas Nikiteas, Gregory Kouraklis, John Griniatsos, Michael Safioleas, Michael Stamatakos, Emmanuel Pikoulis, Antonios Papachristodoulou, Helen Gogas (2006) <i>Anticancer Res</i> <i></i> <i></i> 26: 5B 3749-3753<br/>

http://publicationslist.org/helen.gogas/refid38 2010-10-27T09:02:20Z

Currently, randomized phase III trials have demonstrated that docetaxel is an effective strategy in the adjuvant treatment of breast cancer. However, previous attempts to incorporate docetaxel with an anthracycline in a dose-dense regimen have been unsuccessful. Therefore, new schedules containing both drugs should be explored. Forty-four patients with high-risk operable breast cancer entered this...<br/><br/>George Fountzilas, Dimitrios Pectasides, Christos Christodoulou, Eleni Timotheadou, Theofanis Economopoulos, Pavlos Papakostas, Christos Papadimitriou, Helen Gogas, Ioannis Efstratiou, Dimosthenis Skarlos (2006) <i>Med Oncol</i> <i></i> <i></i> 23: 4 479-488<br/>

http://publicationslist.org/helen.gogas/refid46 2010-10-27T09:02:20Z

Surgical excision following needle-wire localization of nonpalpable, mammographically detected breast lesions is a very valuable diagnostic and therapeutic procedure. No further treatment is usually required after establishing an accurate histological benign diagnosis of indeterminate lesions on preoperative assessment. On the other hand, ductal carcinoma in-situ (DCIS) and early invasive cancer, ...<br/><br/>E Kouskos, G P H Gui, D Mantas, K Revenas, N Rallis, Z Antonopoulou, E Lampadariou, H Gogas, C Markopoulos (2006) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 27: 3 262-266<br/>

http://publicationslist.org/helen.gogas/refid42 2010-10-27T09:02:20Z

OBJECTIVE: It was the aim of this study to investigate the effect of tamoxifen withdrawal on markers of lipid metabolism in postmenopausal women with breast cancer who completed tamoxifen therapy and received no further treatment. METHODS: Lipidemic profile changes were studied in 190 postmenopausal patients with operable breast cancer, following cessation of 5-7 years of tamoxifen treatment. Asse...<br/><br/>C Markopoulos, M Chrissochou, Z Antonopoulou, G Xepapadakis, J Papadiamantis, E Tzoracoleftherakis, H Gogas (2006) <i>Oncology</i> <i></i> <i></i> 70: 4 301-305<br/>

http://publicationslist.org/helen.gogas/refid45 2010-10-27T09:02:20Z

INTRODUCTION: Glycodelin and survivin are key polypeptide regulators of cellular proliferation, apoptosis and angiogenesis. In view of contradictory reports on their functional role in tumors, we studied their transcriptional levels in localized breast cancer. PATIENTS AND METHODS: Glycodelin and survivin messenger ribonucleic acid (mRNA) was isolated and amplified by quantitative reverse-trancrip...<br/><br/>Lida Kostadima, George Pentheroudakis, George Fountzilas, Meletios Dimopoulos, Dimitrios Pectasides, Helen Gogas, Udo Stropp, Christos Christodoulou, Epameinondas Samantas, Ralph Wirtz, Guido Hennig, Dimitrios Bafaloukos, P Arapantoni, Haralambos Kalofonos, Pavlos Papakostas, Theofanis Economopoulos, Aristotelis Bamias, Nicholas Pavlidis (2006) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 100: 2 161-167<br/>

http://publicationslist.org/helen.gogas/refid43 2010-10-27T09:02:20Z

BACKGROUND: There is now increasing evidence that a constitutive expression of cyclooxygenase (COX)-2 plays a role in the development and progression of malignant epithelial tumors. Expression of COX-2 is seen in 93% of melanomas, as determined by immunohistochemistry. Temozolomide (TMZ) has demonstrated activity against melanoma and has been investigated as single agent or in combination. We desi...<br/><br/>H Gogas, A Polyzos, I Stavrinidis, K Frangia, D Tsoutsos, P Panagiotou, C Markopoulos, O Papadopoulos, D Pectasides, M Mantzourani, M Middleton, G Vaiopoulos, G Fountzilas (2006) <i>Ann Oncol</i> <i></i> <i></i> 17: 12 1835-1841<br/>

http://publicationslist.org/helen.gogas/refid54 2010-10-27T09:02:20Z

INTRODUCTION: Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion sub-protocol to the TEAM (Tamoxifen and Exemestane Adjuvant Multicenter) International trial, we compared the effect of the steroidal aromatase inactivator exemestane on th...<br/><br/>C Markopoulos, A Polychronis, V Zobolas, G Xepapadakis, J Papadiamantis, D Koukouras, H Lappas, H Gogas (2005) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 93: 1 61-66<br/>

http://publicationslist.org/helen.gogas/refid55 2010-10-27T09:02:20Z

PURPOSE: The aim of this study was to explore the effect of dose-dense sequential chemotherapy with or without paclitaxel primarily on disease-free survival (DFS) and secondarily on overall survival (OS) in patients with high-risk operable breast cancer. PATIENTS AND METHODS: From June 1997 until November 2000, 604 patients with T1-3N1M0 or T3N0M0 tumors were randomized to three cycles of epirubic...<br/><br/>G Fountzilas, D Skarlos, U Dafni, H Gogas, E Briasoulis, D Pectasides, C Papadimitriou, C Markopoulos, A Polychronis, H P Kalofonos, V Siafaka, P Kosmidis, E Timotheadou, D Tsavdaridis, D Bafaloukos, P Papakostas, E Razis, P Makrantonakis, G Aravantinos, C Christodoulou, A-M Dimopoulos (2005) <i>Ann Oncol</i> <i></i> <i></i> 16: 11 1762-1771<br/>

http://publicationslist.org/helen.gogas/refid56 2010-10-27T09:02:20Z

Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion subprotocol to the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial, we compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile ...<br/><br/>C Markopoulos, M Chrissochou, A Michailidou, E Tzoracoleftherakis, G Xepapadakis, J Papadiamantis, J Misitzis, V Zobolas, D Bafaloukos, H Gogas (2005) <i>Anticancer Drugs</i> <i></i> <i></i> 16: 8 879-883<br/>

http://publicationslist.org/helen.gogas/refid61 2010-10-27T09:02:20Z

BACKGROUND: In the present phase II multicenter study, we assessed the efficacy and tolerability of the combination of gemcitabine and carboplatin in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated, locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m(2) on days 1 and 8 and carboplatin at an AUC of 4 on day 8 of ...<br/><br/>N Xiros, P Papacostas, T Economopoulos, G Samelis, E Efstathiou, E Kastritis, H Kalofonos, A Onyenadum, D Skarlos, A Bamias, H Gogas, D Bafaloukos, E Samantas, P Kosmidis (2005) <i>Ann Oncol</i> <i></i> <i></i> 16: 5 773-779<br/>

http://publicationslist.org/helen.gogas/refid59 2010-10-27T09:02:20Z

Epidemiological, experimental and clinical data strongly support the possibility that breast cancer can be prevented by using anti-estrogenic interventions in healthy women. Four trials involving over 25,000 women have so far been reported using tamoxifen 20 mg/day or placebo in healthy women to chemoprevent breast cancer, and several trials utilizing raloxifene or aromatase inhibitors are underwa...<br/><br/>H Gogas, C Markopoulos, R Blamey (2005) <i>Ann Oncol</i> <i></i> <i></i> 16: 12 1861-1866<br/>

http://publicationslist.org/helen.gogas/refid60 2010-10-27T09:02:20Z

PURPOSE: Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0.6 position of guanine. The methyl adducts are removed by the DNA repair enzyme AGAT. As demonstrated by in vitro studies, cisplatin (CDDP) is able to down-regulate the AGAT activity, suggesting that CDDP could enhance the antitumor activity of TMZ. We designed a randomized phase II study to evaluate and c...<br/><br/>D Bafaloukos, D Tsoutsos, H Kalofonos, S Chalkidou, P Panagiotou, E Linardou, E Briassoulis, E Efstathiou, A Polyzos, G Fountzilas, C Christodoulou, C Kouroussis, T Iconomou, H Gogas (2005) <i>Ann Oncol</i> <i></i> <i></i> 16: 6 950-957<br/>

http://publicationslist.org/helen.gogas/refid58 2010-10-27T09:02:20Z

Paclitaxel (Taxol) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for cancer treatment. This multicenter phase II trial treated 68 patients with advanced breast cancer with paclitaxel (175 mg/m(2) over 3 h) and 3-weekly carboplatin (area under the cur...<br/><br/>George Fountzilas, Dimitrios Pectasides, Anna Kalogera-Fountzila, Dimosthenis Skarlos, Haralambos P Kalofonos, Christos Papadimitriou, Dimitrios Bafaloukos, Stefanos Lambropoulos, Savvas Papadopoulos, Helen Kourea, Christos Markopoulos, Helen Linardou, Dimitrios Mavroudis, Evangelos Briasoulis, Nicholaos Pavlidis, Evangelia Razis, Paraskevas Kosmidis, Helen Gogas (2005) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 92: 1 1-9<br/>

http://publicationslist.org/helen.gogas/refid57 2010-10-27T09:02:20Z

BACKGROUND: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory advanced epithelial ovarian cancer (AEOC). PATIENTS AND METHODS: Patients (pts), who had been treated with platinum or paclitaxel and met the criteria of resistant/refractory ...<br/><br/>Dimosthenis V Skarlos, Haralabos P Kalofonos, George Fountzilas, Meletios A Dimopoulos, Nicholas Pavlidis, Evangelia Razis, Theofanis Economopoulos, Dimitrios Pectasides, Helen Gogas, Paris Kosmidis, Dimitrios Bafaloukos, George Klouvas, George Kyratzis, Gerasimos Aravantinos (2005) <i>Anticancer Res</i> <i></i> <i></i> 25: 4 3103-3108<br/>

http://publicationslist.org/helen.gogas/refid67 2010-10-27T09:02:20Z

The incidence of central nervous system (CNS) metastases in patients with melanoma ranges from 10% to 40% in clinical studies and is even higher in autopsy series with as many as two-thirds of patients with metastatic melanoma having CNS involvement. Treatment options for patients with cerebral metastases are limited and depend largely on the number and the size of the lesions and on the extracran...<br/><br/>D Bafaloukos, H Gogas (2004) <i>Cancer Treat Rev</i> <i></i> <i></i> 30: 6 515-520<br/>

http://publicationslist.org/helen.gogas/refid68 2010-10-27T09:02:20Z

Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and toxicity of temozolomide-based chemotherapy in patients with cerebral metastases f...<br/><br/>Dimitros Bafaloukos, Dimosthenis Tsoutsos, Georges Fountzilas, Helen Linardou, Christos Christodoulou, Haralambos P Kalofonos, Erangelos Briassoulis, Petros Panagiotou, Helen Hatzichristou, Helen Gogas (2004) <i>Melanoma Res</i> <i></i> <i></i> 14: 4 289-294<br/>

http://publicationslist.org/helen.gogas/refid35 2010-10-27T09:02:20Z

OBJECTIVE: To investigate the efficacy and toxicity of gemcitabine administration followed by the combination of fluorouracil (5-FU) modulated by folinic acid in patients with advanced, symptomatic pancreatic cancer. The main objective was to estimate tumour response and any improvement in patients' quality of life. PATIENTS: The study included 48 evaluable patients with metastatic disease with no...<br/><br/>Aristides Polyzos, Nicholas Tsavaris, Christos Kosmas, Helen Gogas, George Koutinos, Nicholas I Nikiteas, Evangelos Felekouras, Gregory Kouraklis, Othon Papadopoulos, Antonios Papachristodoulou, Demetrios Stamatiadis, Michael Safioleas, George Nikou (2004) <i>Clin Drug Investig</i> <i></i> <i></i> 24: 11 661-670<br/>

http://publicationslist.org/helen.gogas/refid66 2010-10-27T09:02:20Z

BACKGROUND: To compare survival between patients with advanced breast cancer (ABC) treated with epirubicin/paclitaxel (Taxol) or paclitaxel/carboplatin (Cp) chemotherapy. PATIENTS AND METHODS: From January 1999 to April 2002, 327 eligible patients with ABC were randomized to receive either paclitaxel 175 mg/m(2) in a 3-h infusion followed by epirubicin (EPI) 80 mg/m(2) (group A) or paclitaxel, as ...<br/><br/>G Fountzilas, H P Kalofonos, U Dafni, C Papadimitriou, D Bafaloukos, P Papakostas, A Kalogera-Fountzila, H Gogas, G Aravantinos, L A Moulopoulos, T Economopoulos, D Pectasides, N Maniadakis, V Siafaka, E Briasoulis, C Christodoulou, D Tsavdaridis, P Makrantonakis, E Razis, P Kosmidis, D Skarlos, M A Dimopoulos (2004) <i>Ann Oncol</i> <i></i> <i></i> 15: 10 1517-1526<br/>

http://publicationslist.org/helen.gogas/refid69 2010-10-27T09:02:20Z

BACKGROUND: High-dose interferon alfa-2b (IFN-alpha2b) as adjuvant therapy for melanoma is associated with substantial dose-limiting toxicity. It has been suggested that the 1-month intravenous (i.v.) induction regimen may be sufficient to reduce the risk of relapse and death. PATIENTS AND METHODS: The Hellenic Cooperative Oncology Group is conducting a multicenter, randomized trial of 1-month i.v...<br/><br/>Helen Gogas, Dimitrios Bafaloukos, John Ioannovich, Dimosthenis Skarlos, Aris Polyzos, George Fountzilas, Haralambos P Kalofonos, Gerassimos Aravantinos, Dimosthenis Tsoutsos, Petros Panagiotou, Konstantina Frangia, Theodora Petrakopoulou, Dimitrios Pectasides (2004) <i>Anticancer Res</i> <i></i> <i></i> 24: 3b 1947-1952<br/>

http://publicationslist.org/helen.gogas/refid70 2010-10-27T09:02:20Z

BACKGROUND: In contrast to autopsy findings, solitary splenic metastases from solid tumors are extremely rare. It may occasionally be the first manifestation of recurrent solid cancers, and in particular of gynecologic malignancies. Secondary amyloidosis is also found in malignancy. CASE: A 52-year-woman originally diagnosed with a Stage IB, grade 2 endometrial carcinoma presented two and a half y...<br/><br/>H Gogas, Th Ignatiadis, Ch Markopoulos, S Karageorgopoulou, D Floros, G Vaiopoulos (2004) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 25: 3 391-393<br/>

http://publicationslist.org/helen.gogas/refid65 2010-10-27T09:02:20Z

The management of patients with metastatic malignant melanoma remains difficult. Conventional chemotherapy has been disappointingly ineffective. Dacarbazine (DTIC) is considered to be one of the most active single agents with a response rate of approximately 15-20%. Many patients who initially respond to treatment subsequently relapse. Clearly, there is a need for improvement, and the evaluation o...<br/><br/>Helen Gogas, Dimitrios Bafaloukos, Agop Y Bedikian (2004) <i>Melanoma Res</i> <i></i> <i></i> 14: 5 415-420<br/>

http://publicationslist.org/helen.gogas/refid62 2010-10-27T09:02:20Z

OBJECTIVES: To evaluate the efficacy and toxicity of the combination of vinorelbine and interleukin (IL)-2 in patients with metastatic melanoma as second-line chemotherapy. PATIENTS AND METHODS: Twenty-two patients with histologically confirmed stage IV melanoma previously treated with temozolomide-based chemotherapy--only one regimen of chemotherapy for disseminated disease was allowed--were trea...<br/><br/>Helen Gogas, D Bafaloukos, G Aravantinos, G Fountzilas, D Tsoutsos, P Panagiotou, K Frangia, H P Kalofonos, E Briasoulis, O Castana, A Polyzos, D Pectasides, J Ioannovich (2004) <i>Cancer Invest</i> <i></i> <i></i> 22: 6 832-839<br/>

http://publicationslist.org/helen.gogas/refid63 2010-10-27T09:02:20Z

PURPOSE: Advanced breast cancer (ABC) is an incurable disease. Standard first-line treatment for patients with HER-2/neu overexpressing tumors includes the combination of the humanized monoclonal antibody trastuzumab with chemotherapy, mainly paclitaxel. This combination is the first to demonstrate a survival advantage in this group of patients. To improve on these results, we investigated a tripl...<br/><br/>George Fountzilas, Christos Christodoulou, Dimitrios Tsavdaridis, Anna Kalogera-Fountzila, Gerassimos Aravantinos, Evangelia Razis, Haralambos P Kalofonos, Pavlos Papakostas, Maria Karina, Helen Gogas, Dimosthenis Skarlos (2004) <i>Cancer Invest</i> <i></i> <i></i> 22: 5 655-662<br/>

http://publicationslist.org/helen.gogas/refid64 2010-10-27T09:02:20Z

Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastat...<br/><br/>D Bafaloukos, C Papadimitriou, H Linardou, G Aravantinos, P Papakostas, D Skarlos, P Kosmidis, G Fountzilas, H Gogas, C Kalofonos, A M Dimopoulos (2004) <i>Br J Cancer</i> <i></i> <i></i> 91: 9 1639-1644<br/>

http://publicationslist.org/helen.gogas/refid76 2010-10-27T09:02:20Z

There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part of the first step of a phase II study, with docetaxel 50 mg/m(2) and gemcitabine 1000 mg/m(2), both administered on day 1 and 8 every 3 weeks up to a total of six cycles. For pati...<br/><br/>Dimosthenis-Vasilios Skarlos, Athanassios-Meletios Dimopoulos, Paraskevas Kosmidis, Pavlos Papakostas, Nicholas Pavlidis, Charalambos Bacoyiannis, Christos Kiamouris, Georgios Klouvas, Helen Gogas, George Fountzilas, Epaminondas Samantas (2003) <i>Lung Cancer</i> <i></i> <i></i> 41: 1 107-111<br/>

http://publicationslist.org/helen.gogas/refid79 2010-10-27T09:02:20Z

Both primary and secondary gallbladder melanomas are rare and, when a solitary melanoma is found in the gallbladder, it is difficult to determine if it is primary or metastatic disease. We report the case of a young woman found to have a single metastatic gallbladder melanoma. Surgical removal of a solitary metastatic focus remains the treatment of choice for isolated metastasis of a malignant mel...<br/><br/>John Gogas, Dimitrios Mantas, Helen Gogas, Efstratios Kouskos, Christos Markopoulos, Stephania Vgenopoulou (2003) <i>Surg Today</i> <i></i> <i></i> 33: 2 135-137<br/>

http://publicationslist.org/helen.gogas/refid77 2010-10-27T09:02:20Z

H Gogas, G Fountzilas (2003) <i>Ann Oncol</i> <i></i> <i></i> 14: 5 667-674<br/>

http://publicationslist.org/helen.gogas/refid75 2010-10-27T09:02:20Z

BACKGROUND: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. PATIENTS AND METHODS: Treatment consisted of vinorelbine 25 mg/m(2) as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m(2), as a 1-h i.v. infusion (day 8). Granuloc...<br/><br/>G Aravantinos, D Bafaloukos, G Fountzilas, C Christodoulou, C Papadimitriou, N Pavlidis, H P Kalofonos, H Gogas, P Kosmidis, M A Dimopoulos (2003) <i>Ann Oncol</i> <i></i> <i></i> 14: 7 1094-1099<br/>

http://publicationslist.org/helen.gogas/refid74 2010-10-27T09:02:20Z

Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disease progression in order to register their clinical course. Median age of the pati...<br/><br/>George Fountzilas, Evangelia Razis, Dimitrios Tsavdaridis, Maria Karina, Stefanos Labropoulos, Christos Christodoulou, Dimitrios Mavroudis, Helen Gogas, Vassilios Georgoulias, Dimosthenis Skarlos (2003) <i>Clin Breast Cancer</i> <i></i> <i></i> 4: 2 120-125<br/>

http://publicationslist.org/helen.gogas/refid72 2010-10-27T09:02:20Z

PURPOSE: Presentation of the results of Tc-99m-sestamibi imaging in the pre-operative localization of parathyroid adenomas and the intra-operative localization of those lesions using a gamma detector (prospective study). PATIENTS & METHODS: Eighteen consecutive patients aged 27-75 years with primary hyperparathyroidism (PHPT) underwent Tc-99m-sestamibi scanning 1-2 hours before the operation and t...<br/><br/>J Gogas, E Kouskos, D Mantas, C Markopoulos, D Kyriaki, S Tseleni-Balafouta, H Gogas, A Kostakis (2003) <i>Acta Chir Belg</i> <i></i> <i></i> 103: 6 626-630<br/>

http://publicationslist.org/helen.gogas/refid71 2010-10-27T09:02:20Z

This phase II trial studied the efficacy and toxicity of full dose paclitaxel plus vinorelbine, as salvage chemotherapy in patients with metastatic breast cancer resistant to anthracyclines. Patients received vinorelbine (30 mg/m2) followed 1 hour later by full dose paclitaxel (175 mg/m2) every 3 weeks for a maximum of 8 cycles or until disease progression. Because of the heavy pretreatment of the...<br/><br/>A Polyzos, N Tsavaris, C Kosmas, H Gogas, H Toufexi, C Kosmidis, C Markopoulos, A Giannopoulos, O Papadopoulos, D Stamatiadis, G Kouraklis (2003) <i>J Chemother</i> <i></i> <i></i> 15: 6 607-612<br/>

http://publicationslist.org/helen.gogas/refid73 2010-10-27T09:02:20Z

This phase II trial studied the efficacy and toxicity of docetaxel-epirubicin, supported by granulocyte colony-stimulating factor, as first-line chemotherapy in metastatic breast cancer. Patients received epirubicin (60 mg/m2) followed 1 hour later by docetaxel (80 mg/m2) every 3 weeks for a maximum of 8 cycles or until disease progression. Prophylactic granulocyte colony-stimulating factor (5 mic...<br/><br/>Aristides Polyzos, Nicholas Tsavaris, Christos Kosmas, Helen Gogas, Maria Vadiaka, Christos Markopoulos, Athanasios Giannopoulos, Nicholas Kalahanis, Demetrios Stamatiadis, Gregory Kouraklis, Gabriel Karatzas, Christos Liapis, Konstantinos Syrigos (2003) <i>Anticancer Res</i> <i></i> <i></i> 23: 3C 2917-2923<br/>

http://publicationslist.org/helen.gogas/refid85 2010-10-27T09:02:20Z

The purpose of this study was to address the prognostic significance of circulating melanoma cells by reverse transcriptase-polymerase chain reaction in the peripheral blood of stage IIB and III melanoma patients on high-dose adjuvant interferon at multiple sequential time points from initiation of treatment. Tyrosinase mRNA in peripheral blood from these patients was assayed by reverse transcript...<br/><br/>H Gogas, G Kefala, D Bafaloukos, K Frangia, A Polyzos, D Pectasides, D Tsoutsos, P Panagiotou, J Ioannovich, D Loukopoulos (2002) <i>Br J Cancer</i> <i></i> <i></i> 87: 2 181-186<br/>

http://publicationslist.org/helen.gogas/refid84 2010-10-27T09:02:20Z

Granular cell tumor (GCT) is an uncommon, usually benign tumor that occasionally involves the breast. It is possibly of neural origin (Schwann cells) and usually occurs in premenopausal black women. Physical examination, mammographic, ultrasonographic findings and pathologic examination may suggest breast malignancy. Positive immunohistochemical staining of the cells for S-100 protein, NSE, and CE...<br/><br/>J Gogas, C Markopoulos, E Kouskos, H Gogas, D Mantas, Z Antonopoulou, K Kontzoglou (2002) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 23: 4 333-334<br/>

http://publicationslist.org/helen.gogas/refid86 2010-10-27T09:02:20Z

Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can also inhibit growth of pancreatic cancer xenografts in vivo. Thirty-six patients with advanced pancr...<br/><br/>T R J Evans, K W Colston, F J Lofts, D Cunningham, D A Anthoney, H Gogas, J S de Bono, K J Hamberg, T Skov, J L Mansi (2002) <i>Br J Cancer</i> <i></i> <i></i> 86: 5 680-685<br/>

http://publicationslist.org/helen.gogas/refid89 2010-10-27T09:02:20Z

PURPOSE: Temozolomide is a novel oral alkylating agent that is effective against melanoma. Moreover, temozolomide readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. This phase II study was performed to assess the efficacy and safety of the combination regimen of temozolomide and docetaxel in patients with advanced metastatic melanoma. PATIE...<br/><br/>D Bafaloukos, H Gogas, V Georgoulias, E Briassoulis, G Fountzilas, E Samantas, Ch Kalofonos, D Skarlos, A Karabelis, P Kosmidis (2002) <i>J Clin Oncol</i> <i></i> <i></i> 20: 2 420-425<br/>

http://publicationslist.org/helen.gogas/refid83 2010-10-27T09:02:20Z

Cystic breast masses are very common in female patients attending breast clinics. Most of them are benign and managed by simple aspiration. We reviewed histology records for the last 12 years to find patients with cystic breast carcinomas and to evaluate special clinical signs that may help to identify patients with this rare entity. Eighteen patients with cystic breast carcinomas were found among...<br/><br/>Christos Markopoulos, Efstratios Kouskos, Helen Gogas, John Kakisis, Vasiliki Kyriakou, John Gogas, Alkis Kostakis (2002) <i>Am Surg</i> <i></i> <i></i> 68: 9 783-786<br/>

http://publicationslist.org/helen.gogas/refid87 2010-10-27T09:02:20Z

PURPOSE: This is the first study to evaluate the tolerability and activity of liposomal doxorubicin (Caelyx; Schering-Plough Pharmaceuticals) < or =60 mg/km(2) in patients with locally recurrent breast cancer, when administered in conjunction with reirradiation and local hyperthermia treatment. EXPERIMENTAL DESIGN: Fifteen female patients, who had undergone a radical mastectomy and conventional ra...<br/><br/>Vassilios E Kouloulias, Costas E Dardoufas, John R Kouvaris, Costas S Gennatas, Aris K Polyzos, Helen J Gogas, Panagiotis H Sandilos, Nikolaos K Uzunoglu, Elias G Malas, Lambros J Vlahos (2002) <i>Clin Cancer Res</i> <i></i> <i></i> 8: 2 374-382<br/>

http://publicationslist.org/helen.gogas/refid81 2010-10-27T09:02:20Z

BACKGROUND: To determine the activity and safety of the combination of paclitaxel and pegylated liposomal doxorubicin (Caelyx) in patients with locally advanced breast cancer. PATIENTS AND METHODS: This was a multicenter phase II study. Thirty-five newly diagnosed patients with locally advanced breast cancer were included in the study. Histological or cytological diagnosis was necessary for inclus...<br/><br/>H Gogas, C Papadimitriou, H P Kalofonos, D Bafaloukos, G Fountzilas, D Tsavdaridis, A Anagnostopoulos, A Onyenadum, P Papakostas, T Economopoulos, C Christodoulou, P Kosmidis, C Markopoulos (2002) <i>Ann Oncol</i> <i></i> <i></i> 13: 11 1737-1742<br/>

http://publicationslist.org/helen.gogas/refid80 2010-10-27T09:02:20Z

Immunologic effects of high-dose interferon are still unclear. We have evaluated changes in blood lymphocyte subpopulations, immunoglobulins, and multiple interleukin in patients with high-risk cutaneous melanoma on adjuvant treatment with high-dose interferon and compared pretreatment values with normal controls. Samples were obtained before treatment, 1 month after induction treatment and at 3, ...<br/><br/>Helen Gogas, George Paterakis, Konstantina Frangia, Dimitrios Bafaloukos, Dimitrios Pectasides, Haralambos P Kalofonos, Dimitrios Loukopoulos, Cathrin Stavropoulou-Giokas, John Ioannovich, Martin C Mihm (2002) <i>Am J Clin Oncol</i> <i></i> <i></i> 25: 6 591-596<br/>

http://publicationslist.org/helen.gogas/refid78 2010-10-27T09:02:20Z

John Gogas, Efstratios Kouskos, Christos Markopoulos, Athina Androulakis, Dimitrios Mantas, Helen Gogas, Alkiviadis Kostakis (2002) <i>Eur J Surg</i> <i></i> <i></i> 168: 10 572-574<br/>

http://publicationslist.org/helen.gogas/refid30 2010-10-27T09:02:20Z

As the incidence of malignant melanoma steadily increases the need for markers in detection of early metastasis and guidance of therapy has become urgent. Presence of melanoma cells in patient peripheral blood, lymph nodes or bone marrow (BM) specimens could indicate tumour dissemination, and thus a high risk of metastasis. In 1991 coupled Reverse Transcription and Polymerase Chain Reaction (RT-PC...<br/><br/>G Kefala, H Gogas (2002) <i>J BUON</i> <i></i> <i></i> 7: 4 325-330<br/>

http://publicationslist.org/helen.gogas/refid82 2010-10-27T09:02:20Z

OBJECTIVES: The number of agents that are active in patients with metastatic melanoma is limited and cure is not a realistic objective for treatment at this stage. The aim of the study was to evaluate the efficacy and safety of new combination regimen cosisting of docetaxel and dacarbazine (DTIC), as first-line chemotherapy, in patients with advanced melanoma. PATIENTS AND METHODS: Patients with a...<br/><br/>D Bafaloukos, G Aravantinos, G Fountzilas, G Stathopoulos, H Gogas, G Samonis, E Briasoulis, N Mylonakis, D V Skarlos, P Kosmidis (2002) <i>Oncology</i> <i></i> <i></i> 63: 4 333-337<br/>

http://publicationslist.org/helen.gogas/refid91 2010-10-27T09:02:20Z

C Markopoulos, E Kouskos, M Dimitrios, K Kontzoglou, H Pappis, A Galanos, H Gogas (2001) <i>J Am Geriatr Soc</i> <i></i> <i></i> 49: 7 1004-1005<br/>

http://publicationslist.org/helen.gogas/refid90 2010-10-27T09:02:20Z

J Gogas, C Markopoulos, E Kouskos, H Gogas, V Kiriakou (2001) <i>Eur J Surg</i> <i></i> <i></i> 167: 9 715-718<br/>

http://publicationslist.org/helen.gogas/refid88 2010-10-27T09:02:20Z

AIM: To evaluate the activity and acute toxicity of the combination of weekly paclitaxel as first-line chemotherapy and trastuzumab, in patients with HER-2/neu overexpressing advanced breast cancer (ABC). BACKGROUND: Weekly paclitaxel has been shown to be a well tolerated treatment with considerable activity in patients with ABC. Clinical trials with transtuzumab, a humanized anti-p185 HER-2/neu m...<br/><br/>G Fountzilas, D Tsavdaridis, A Kalogera-Fountzila, C H Christodoulou, E Timotheadou, C H Kalofonos, P Kosmidis, A Adamou, P Papakostas, H Gogas, G Stathopoulos, E Razis, D Bafaloukos, D Skarlos (2001) <i>Ann Oncol</i> <i></i> <i></i> 12: 11 1545-1551<br/>

http://publicationslist.org/helen.gogas/refid92 2010-10-27T09:02:20Z

The purpose of this study was to determine factors associated with the incidence of axillary lymph node metastases (ALNM) in T1 tumors and cases in which axillary dissection could be omitted. Data from 195 patients with T1 primary invasive breast cancer (size < or = 2 cm) who underwent either mastectomy or wide local excision of the tumor and axillary dissection were reviewed. ALNM was found in 59...<br/><br/>C Markopoulos, E Kouskos, H Gogas, D Mandas, J Kakisis, J Gogas (2000) <i>Am Surg</i> <i></i> <i></i> 66: 11 1011-1013<br/>

http://publicationslist.org/helen.gogas/refid95 2010-10-27T09:02:20Z

Four cases of radial scar of the breast, primarily diagnosed as carcinoma are presented; the patients were found among 858 patients who were operated on at our Breast Unit over the last 4 years. The lesion was revealed on routine mammographic examination in 4 of our patients, while in the fourth it was found by palpation. In two of our patients mammographic examination revealed architectural disto...<br/><br/>C Markopoulos, J Kakisis, K Koufopoulos, P Alevras, H Gogas, D Tziortziotis, D Floros (1999) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 20: 2 147-149<br/>

http://publicationslist.org/helen.gogas/refid94 2010-10-27T09:02:20Z

BACKGROUND: Bone-marrow micrometastases have been found in patients with primary breast cancer. We report long-term follow-up of women with primary breast cancer, diagnosed between 1981 and 1986, who had multiple aspirates taken at the time of initial surgery. METHODS: 350 women with primary breast cancer were examined immunocytochemically with antibody to epithelial membrane antigen. We investiga...<br/><br/>J L Mansi, H Gogas, J M Bliss, J C Gazet, U Berger, R C Coombes (1999) <i>Lancet</i> <i></i> <i></i> 354: 9174 197-202<br/>

http://publicationslist.org/helen.gogas/refid93 2010-10-27T09:02:20Z

BACKGROUND: Adenocarcinoma of unknown primary comprises up to 10% of metastatic malignant disease. With few exceptions this diagnosis carries a very poor prognosis of a few months with minimal survival advantage to chemotherapy. However there is the possibility that chemotherapy can improve symptom control and quality of life. PATIENTS AND METHODS: Forty-four patients with adenocarcinoma of unknow...<br/><br/>F J Lofts, H Gogas, J L Mansi (1999) <i>Ann Oncol</i> <i></i> <i></i> 10: 11 1389-1392<br/>

http://publicationslist.org/helen.gogas/refid99 2010-10-27T09:02:20Z

Thirty-nine patients with inoperable adenocarcinoma of the pancreas were studied (27 male, 12 female; median age 60 years, range 39-75 years). All patients received chemotherapy with continuous infusion 5-fluorouracil with intravenous bolus epirubicin followed by cisplatin, repeated every 21 days for a total of six cycles and were evaluable for response. Serum CA19-9 concentrations were obtained a...<br/><br/>H Gogas, F J Lofts, T R Evans, S Daryanani, J L Mansi (1998) <i>Br J Cancer</i> <i></i> <i></i> 77: 2 325-328<br/>

http://publicationslist.org/helen.gogas/refid98 2010-10-27T09:02:20Z

C Markopoulos, F Sampalis, H Gogas, P Despotidis, V Kyriakou (1998) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 19: 3 246-248<br/>

http://publicationslist.org/helen.gogas/refid96 2010-10-27T09:02:20Z

We report a case of meningioma subsequently developed in a patient with bilateral breast carcinoma, which was originally thought to be single brain metastases. A brief review of the literature is presented with emphasis on the unique association between the two neoplasms, which suggests a possible hormonal relationship. The knowledge of this association is important in the differential diagnosis o...<br/><br/>C Markopoulos, F Sampalis, N Givalos, H Gogas (1998) <i>Eur J Surg Oncol</i> <i></i> <i></i> 24: 4 332-334<br/>

http://publicationslist.org/helen.gogas/refid97 2010-10-27T09:02:20Z

Mucoepidermoid carcinomas are very rare breast tumors. The morphology of this breast tumour is similar to its counterpart in the salivary gland. The first two cases reported were low-grade and neither patient had metastatic disease. Furthermore, none of the five patients with low-grade mucoepidermoid carcinoma reported by Fisher had axillary lymph node involvement and were alive with no evidence o...<br/><br/>C Markopoulos, H Gogas, A Livaditou, D Floros (1998) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 19: 3 291-293<br/>

http://publicationslist.org/helen.gogas/refid101 2010-10-27T09:02:20Z

To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC), we treated 70 consecutive patients with epirubicin 80 mg m(-2) i.v. on day 1 and etoposide 200 mg o.d. p.o. on days 1-4 (EE) at 3-weekly intervals. The median age of patients was 64 years (range 39-84). The male-female ratio was 42:28 and 35 (50%) had metastatic disease. Fifty-seven pati...<br/><br/>H Gogas, F J Lofts, T R Evans, F J Millard, R Wilson, J L Mansi (1997) <i>Br J Cancer</i> <i></i> <i></i> 76: 5 639-642<br/>

http://publicationslist.org/helen.gogas/refid100 2010-10-27T09:02:20Z

A rare case of metachronous bilateral Paget's disease of the nipple is presented. The occasional failure of routine follow-up to detect certain tumours until biologically advanced and the value of patient observations are mentioned.<br/><br/>C Markopoulos, H Gogas, F Sampalis, B Kyriakou (1997) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 18: 6 495-496<br/>

http://publicationslist.org/helen.gogas/refid106 2010-10-27T09:02:20Z

Endometriosis of a surgical scar is rare and occurs mainly when a hysterectomy has been performed in the past. Development of malignancy in such a lesion is very unusual. A rare case of primary endometrioid carcinoma in the endometriosis of a caesarean scar is described.<br/><br/>C Markopoulos, H Gogas, G Eleftheriou, D Floros (1996) <i>Eur J Gynaecol Oncol</i> <i></i> <i></i> 17: 6 520-521<br/>

http://publicationslist.org/helen.gogas/refid105 2010-10-27T09:02:20Z

A retrospective review was undertaken to obtain more precise information about neurotoxicity, nephrotoxicity, and the effects of dexamethasone on the frequency and severity of hyperglycemia in diabetic patients with epithelial ovarian cancer treated with paclitaxel and/or cisplatin. Thirty-three patients were identified from 1254 patients over a 10-year period. In the cisplatin-treated patients, 2...<br/><br/>H Gogas, F Shapiro, C Aghajanian, D Fennelly, L Almadrones, W J Hoskins, D R Spriggs (1996) <i>Gynecol Oncol</i> <i></i> <i></i> 61: 1 22-26<br/>

http://publicationslist.org/helen.gogas/refid104 2010-10-27T09:02:20Z

H Gogas, J L Mansi (1996) <i>Cancer Treat Rev</i> <i></i> <i></i> 21: 6 541-552<br/>

http://publicationslist.org/helen.gogas/refid103 2010-10-27T09:02:20Z

An elderly Caucasian woman with a 2-year-history of hypothyroidism, treated with thyroxine, presented with a rapidly growing mass in the thyroid. The morphological and immunological features of this thyroid tumour were those of a peripheral T-cell lymphoma with an immunophenotype commonly associated with HTLV-1 positive-adult T-cell leukaemia/lymphoma, although serology for HTLV1 antibody was nega...<br/><br/>Z H Abdul-Rahman, H J Gogas, J A Tooze, B Anderson, J Mansi, N P Sacks, C J Finlayson (1996) <i>Histopathology</i> <i></i> <i></i> 29: 5 455-459<br/>

http://publicationslist.org/helen.gogas/refid102 2010-10-27T09:02:20Z

Avascular necrosis has long been recognized as a complication of glucorticoid therapy. With the recent recognition of paclitaxel's activity in advanced ovarian cancer, increasing attention has been focused on the concomitant use of corticosteroid premedication and its associated morbidities. This report describes avascular necrosis occurring in a patient receiving chemotherapy with corticosteroid ...<br/><br/>H Gogas, D Fennelly (1996) <i>Gynecol Oncol</i> <i></i> <i></i> 63: 3 379-381<br/>

http://publicationslist.org/helen.gogas/refid107 2010-10-27T09:02:20Z

Cytologic specimens (FNA) from 42 primary invasive ductal breast carcinomas and 22 matched specimens of cancer tissue were tested for EGFR status, PCNA index and vimentin expression by immunocytochemical staining, using an Extravidin-Biotin method, and their relationship with various prognostic factors was investigated. EGFR positivity, high PC10 score and vimentin positivity were significantly co...<br/><br/>H Koutselini, C Markopoulos, S Lambropoulou, H Gogas, C Kandaraki, J Gogas (1995) <i>Cytopathology</i> <i></i> <i></i> 6: 1 14-21<br/>

http://publicationslist.org/helen.gogas/refid108 2010-10-27T09:02:20Z

Hamartomas of the breast are rare tumor-like lesions composed of ducts, lobules, fat, and fibrous tissue. The clinical and pathologic findings of six cases of patients ranging in age from 19 to 63 years are reported. Diagnosis is difficult, and we emphasize that fine needle aspiration and cytology of the smears is not diagnostic for hamartomas.<br/><br/>J Gogas, C Markopoulos, H Gogas, P Skandalakis, K Kontzoglou, A Stavridou (1994) <i>Am Surg</i> <i></i> <i></i> 60: 6 447-450<br/>

http://publicationslist.org/helen.gogas/refid109 2010-10-27T09:02:20Z

Seventy-eight confirmed cases of second primary breast cancer in the contralateral breast were encountered over a 22-year period in 1332 women with invasive breast cancer treated in our department. Tumors were grouped into those simultaneously detected in both breasts or within 6 months of each other (synchronous, 1.6%) and those detected within more than 6 months (metachronous, 4.2%). The mean in...<br/><br/>J Gogas, C Markopoulos, P Skandalakis, H Gogas (1993) <i>Am Surg</i> <i></i> <i></i> 59: 11 733-735<br/>

http://publicationslist.org/helen.gogas/refid110 2010-10-27T09:02:20Z

J G Dervenoulas, H J Gogas, M C Lazanas, A A Megalou, S A Raptis (1993) <i>AIDS</i> <i></i> <i></i> 7: 2 290-291<br/>